Literature DB >> 12324669

Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease.

G C Donaldson1, T A R Seemungal, A Bhowmik, J A Wedzicha.   

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is characterised by both an accelerated decline in lung function and periods of acute deterioration in symptoms termed exacerbations. The aim of this study was to investigate whether these are related.
METHODS: Over 4 years, peak expiratory flow (PEF) and symptoms were measured at home daily by 109 patients with COPD (81 men; median (IQR) age 68.1 (63-74) years; arterial oxygen tension (PaO(2)) 9.00 (8.3-9.5) kPa, forced expiratory volume in 1 second (FEV(1)) 1.00 (0.7-1.3) l, forced vital capacity (FVC) 2.51 (1.9-3.0) l); of these, 32 (29 men) recorded daily FEV(1). Exacerbations were identified from symptoms and the effect of frequent or infrequent exacerbations (> or < 2.92 per year) on lung function decline was examined using cross sectional, random effects models.
RESULTS: The 109 patients experienced 757 exacerbations. Patients with frequent exacerbations had a significantly faster decline in FEV(1) and peak expiratory flow (PEF) of -40.1 ml/year (n=16) and -2.9 l/min/year (n=46) than infrequent exacerbators in whom FEV(1) changed by -32.1 ml/year (n=16) and PEF by -0.7 l/min/year (n=63). Frequent exacerbators also had a greater decline in FEV(1) if allowance was made for smoking status. Patients with frequent exacerbations were more often admitted to hospital with longer length of stay. Frequent exacerbations were a consistent feature within a patient, with their number positively correlated (between years 1 and 2, 2 and 3, 3 and 4).
CONCLUSIONS: These results suggest that the frequency of exacerbations contributes to long term decline in lung function of patients with moderate to severe COPD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12324669      PMCID: PMC1746193          DOI: 10.1136/thorax.57.10.847

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  22 in total

1.  Risk factors for hospitalization for a chronic obstructive pulmonary disease exacerbation. EFRAM study.

Authors:  J Garcia-Aymerich; E Monsó; R M Marrades; J Escarrabill; M A Félez; J Sunyer; J M Antó
Journal:  Am J Respir Crit Care Med       Date:  2001-09-15       Impact factor: 21.405

2.  Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations.

Authors:  A Bhowmik; T A Seemungal; R J Sapsford; J A Wedzicha
Journal:  Thorax       Date:  2000-02       Impact factor: 9.139

3.  Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.

Authors:  N Soler; S Ewig; A Torres; X Filella; J Gonzalez; A Zaubet
Journal:  Eur Respir J       Date:  1999-11       Impact factor: 16.671

4.  Association between airway bacterial load and markers of airway inflammation in patients with stable chronic bronchitis.

Authors:  A T Hill; E J Campbell; S L Hill; D L Bayley; R A Stockley
Journal:  Am J Med       Date:  2000-09       Impact factor: 4.965

5.  Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease.

Authors:  T A Seemungal; G C Donaldson; A Bhowmik; D J Jeffries; J A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2000-05       Impact factor: 21.405

6.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial.

Authors:  P S Burge; P M Calverley; P W Jones; S Spencer; J A Anderson; T K Maslen
Journal:  BMJ       Date:  2000-05-13

Review 7.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary.

Authors:  R A Pauwels; A S Buist; P M Calverley; C R Jenkins; S S Hurd
Journal:  Am J Respir Crit Care Med       Date:  2001-04       Impact factor: 21.405

8.  Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD.

Authors:  M Miravitlles; C Espinosa; E Fernández-Laso; J A Martos; J A Maldonado; M Gallego
Journal:  Chest       Date:  1999-07       Impact factor: 9.410

9.  Acute exacerbation of COPD: factors associated with poor treatment outcome.

Authors:  N A Dewan; S Rafique; B Kanwar; H Satpathy; K Ryschon; G S Tillotson; M S Niederman
Journal:  Chest       Date:  2000-03       Impact factor: 9.410

10.  Lower respiratory illnesses promote FEV(1) decline in current smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the lung health study.

Authors:  R E Kanner; N R Anthonisen; J E Connett
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

View more
  640 in total

1.  RIG-like helicase innate immunity inhibits vascular endothelial growth factor tissue responses via a type I IFN-dependent mechanism.

Authors:  Bing Ma; Charles S Dela Cruz; Dominik Hartl; Min-Jong Kang; Shervin Takyar; Robert J Homer; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Crit Care Med       Date:  2011-01-28       Impact factor: 21.405

2.  [Antimicrobial treatment of patients with severe acute exacerbation of COPD].

Authors:  B Klapdor; S Ewig
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-03-22       Impact factor: 0.840

3.  Chronic obstructive pulmonary disease exacerbations: accurate and easy measurement promises much.

Authors:  Stephen I Rennard; Kristina L Bailey
Journal:  Am J Respir Crit Care Med       Date:  2012-06-01       Impact factor: 21.405

4.  Lung function decrement with arsenic exposure to drinking groundwater along River Indus: a comparative cross-sectional study.

Authors:  Asaad Ahmed Nafees; Ambreen Kazi; Zafar Fatmi; Muhammad Irfan; Arif Ali; Fujio Kayama
Journal:  Environ Geochem Health       Date:  2010-07-15       Impact factor: 4.609

Review 5.  Inhaled corticosteroids in chronic obstructive pulmonary disease: a pro-con perspective.

Authors:  K Suresh Babu; Jack A Kastelik; Jaymin B Morjaria
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

6.  Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease. What We Know and Can Do for Our Patients.

Authors:  Ariel Jaitovich; Esther Barreiro
Journal:  Am J Respir Crit Care Med       Date:  2018-07-15       Impact factor: 21.405

7.  Cigarette smoke and HIV synergistically affect lung pathology in cynomolgus macaques.

Authors:  Hitendra S Chand; Rodrigo Vazquez-Guillamet; Christopher Royer; Karin Rudolph; Neerad Mishra; Shashi P Singh; Shah S Hussain; Edward Barrett; Shannon Callen; Siddappa N Byrareddy; Maria Cristina Vazquez Guillamet; Jawad Abukhalaf; Aryaz Sheybani; Vernat Exil; Veena Raizada; Hemant Agarwal; Madhavan Nair; Francois Villinger; Shilpa Buch; Mohan Sopori
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

8.  Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.

Authors:  Dheeraj Gupta; Ritesh Agarwal; Ashutosh Nath Aggarwal; V N Maturu; Sahajal Dhooria; K T Prasad; Inderpaul S Sehgal; Lakshmikant B Yenge; Aditya Jindal; Navneet Singh; A G Ghoshal; G C Khilnani; J K Samaria; S N Gaur; D Behera
Journal:  Lung India       Date:  2013-07

9.  A ferret model of COPD-related chronic bronchitis.

Authors:  S Vamsee Raju; Hyunki Kim; Stephen A Byzek; Li Ping Tang; John E Trombley; Patricia Jackson; Lawrence Rasmussen; J Michael Wells; Emily Falk Libby; Erik Dohm; Lindy Winter; Sharon L Samuel; Kurt R Zinn; J Edwin Blalock; Trenton R Schoeb; Mark T Dransfield; Steven M Rowe
Journal:  JCI Insight       Date:  2016-09-22

10.  Evolution of the COPD Assessment Test score during chronic obstructive pulmonary disease exacerbations: determinants and prognostic value.

Authors:  Darwin Feliz-Rodriguez; Santiago Zudaire; Carlos Carpio; Elizabet Martínez; Antonia Gómez-Mendieta; Ana Santiago; Rodolfo Alvarez-Sala; Francisco García-Río
Journal:  Can Respir J       Date:  2013 Sep-Oct       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.